11月 2025
- 首頁
- Concord Biotech
11月 2025Concord Biotech的市場佔有率分析
Concord Biotech Limited is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation based biopharmaceutical active pharmaceutical ingredients sold worldwide.
Concord was founded in 2000 by Sudhir Vaid.
Concord Biotech(包含公司地區)
查看更多網站流量與參與度資訊- concordbiotech.com
Concord Biotech截至 11月 2025 的總收入為 > 1B
Concord Biotech 熱門網域產生的總收入
Concord Biotech 熱門網域 3 年內的總收入
Concord Biotech 熱門網域的總收入
Concord Biotech的熱門網域總造訪量
了解Concord Biotech市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
Concord Biotech的熱門網域平均造訪時長
分析Concord Biotech參與度指標。
過去 3 個月平均造訪時長
子公司細目
Concord Biotech的熱門網域平均頁面瀏覽量
了解Concord Biotech如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自Concord Biotech
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Concord Biotech Limited had issues with marketing approval for its teriflunomide 7 mg and 14 mg tablets on Apr 8th '25.Concord Biotech on Tuesday, April 8, announced that it received marketing approval for its teriflunomide 7 mg and 14 mg tablets from the United States Food and Drug Administration (USFDA).
4月 8, 2025閱讀更多
新聞Concord Biotech Limited invested into Palvella Therapeutics, Inc $1M on Dec 12th '24.Concord Biotech Ltd on Thursday said it has invested USD 10 lakh (nearly Rs 85 crore) in US-based Palvella Therapeutics, Inc with an aim to establish a partnership to manufacture and commercialise 'Qtorin', a drug used to treat serious and rare genetic skin diseases.
12月 12, 2024閱讀更多
新聞Concord Biotech Limited went public on Aug 18th '23.Concord Biotech's IPO was backed by the Jhunjhunwala family when the shares debuted in August 2023.
5月 27, 2024閱讀更多
查看所有Concord Biotech信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。